- Home
- PHAR vs PML Comparison
PHAR vs PML Comparison
Compare PHAR & PML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- PML
- Stock Information
- Founded
- PHAR 1988
- PML 2002
- Country
- PHAR Netherlands
- PML United States
- Employees
- PHAR N/A
- PML N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- PML Investment Managers
- Sector
- PHAR Health Care
- PML Finance
- Exchange
- PHAR Nasdaq
- PML Nasdaq
- Market Cap
- PHAR 718.1M
- PML 508.5M
- IPO Year
- PHAR N/A
- PML N/A
- Fundamental
- Price
- PHAR $10.65
- PML $7.45
- Analyst Decision
- PHAR Strong Buy
- PML
- Analyst Count
- PHAR 3
- PML 0
- Target Price
- PHAR $30.00
- PML N/A
- AVG Volume (30 Days)
- PHAR 4.4K
- PML 188.0K
- Earning Date
- PHAR 07-31-2025
- PML 01-01-0001
- Dividend Yield
- PHAR N/A
- PML 5.65%
- EPS Growth
- PHAR N/A
- PML N/A
- EPS
- PHAR N/A
- PML N/A
- Revenue
- PHAR $320,708,000.00
- PML N/A
- Revenue This Year
- PHAR $13.31
- PML N/A
- Revenue Next Year
- PHAR $7.68
- PML N/A
- P/E Ratio
- PHAR N/A
- PML N/A
- Revenue Growth
- PHAR 24.13
- PML N/A
- 52 Week Low
- PHAR $6.65
- PML $6.92
- 52 Week High
- PHAR $12.61
- PML $9.46
- Technical
- Relative Strength Index (RSI)
- PHAR 49.05
- PML 51.44
- Support Level
- PHAR $10.46
- PML $7.33
- Resistance Level
- PHAR $11.49
- PML $7.45
- Average True Range (ATR)
- PHAR 0.36
- PML 0.06
- MACD
- PHAR -0.12
- PML 0.02
- Stochastic Oscillator
- PHAR 31.46
- PML 83.50
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About PML Pimco Municipal Income Fund II of Beneficial Interest
PIMCO Municipal Income Fund II is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal income tax. The fund portfolio of investments consists of investments in different sectors such as education, healthcare, and others.